Open AccessS169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER‐RISK MYELODYSPLASTIC SYNDROMES
Author(s) -
Kubasch A. S.,
Giagounidis A.,
Metzgeroth G.,
Jonasova A.,
Herbst R.,
Diaz J. M. T.,
De Renzis B.,
Götze K. S.,
HuetterKroenke M.L.,
Gourin M.P.,
Slama B.,
DimicoliSalazar S.,
ConyMakhoul P.,
Laribi K.,
Park S.,
Jersemann K.,
Schipp D.,
Metzeler K. H.,
Tiebel O.,
Sockel K.,
Gloaguen S.,
Mies A.,
Chermat F.,
Thiede C.,
Sapena R.,
Schlenk R. F.,
Fenaux P.,
Platzbecker U.,
Ades L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843568.62728.76
Subject(s) - medicine , romiplostim , myelodysplastic syndromes , eltrombopag , thrombopoietin , international prognostic scoring system , thrombopoietin receptor , prospective cohort study , clinical endpoint , oncology , cohort , platelet , clinical trial , bone marrow , haematopoiesis , immune thrombocytopenia , genetics , stem cell , biology